Member Info for Sangijuelas1

RNS on the way.

Could just be a TR1 or could be something else

Interesting. I have always put the steep rise prior to the Blautix results to a pump and dump. But maybe it was driven as well by these shorts closing as they were messing with the price for a couple of months before the rise

Look at how the same transaction broken up into smaller ones brings the price down

14:39:21 69.30 1,278 Sell* 885.65 A
14:39:21 69.50 1,536 Buy* 1,068 A
14:39:21 69.50 864 Buy* 600.48 A
14:39:21 69.50 322 Sell* 223.79 A
14:39:21 69.70 800 Sell* 557.60 A
14:39:21 69.70 400 Sell* 278.80 A
14:39:21 69.70 400 Sell* 278.80 A
14:39:21 69.70 1,600 Sell* 1,115 A
14:39:21 69.70 1,000 Sell* 697.00 A
14:39:00 69.50 1,600 Sell* 1,112 A
14:39:00 69.50 800 Sell* 556.00 A
14:39:00 69.50 800 Sell* 556.00 A
14:39:00 70.00 50 Sell* 35.00 A

They are short sellers controlling the price. It is all day every day as there are not enough buyers to blow them out of the water.

Shortie still having a go

14:16:23 70.00 593 Sell* 415.10 A
14:16:23 70.00 800 Sell* 560.00 A
14:16:23 70.00 2,000 Sell* 1,400 A
14:16:23 70.00 800 Sell* 560.00 A
14:16:23 70.00 1,600 Sell* 1,120 A
14:16:23 70.00 1,600 Sell* 1,120 A
14:16:23 70.00 824 Sell* 576.80 A
14:16:23 70.00 776 Sell* 543.20

It's a presentation at an event hosted by Oppenheimer where they make themselves available for 1-1 meetings with institutional investors.

You aren't going to find a buyer for the company there. It's likely they will look to raise next year. They also need to raise awareness to get broker recommendations

https://mobile.twitter.com/4dpharmaplc/status/1440201628762714112

Shorts having to work a bit harder

12:14:24 66.60 2,307 Sell* 1,536 A 12:14:24 66.60 367 Sell* 244.42 A
12:14:24 66.60 1,940 Sell* 1,292 12:14:24 66.10 256 Sell* 169.22 A
12:14:24 66.20 886 Sell* 586.53 A 12:14:24 66.20 1,700 Sell* 1,125 A
12:14:24 66.20 2,007 Sell* 1,329 A
12:14:24 66.60 2,036 Sell* 1,356 A
12:14:24 66.60 271 Sell* 180.49 A
12:14:24 66.20 4,782 Sell* 3,166 A
12:14:24 66.20 2,007 Sell* 1,329 A
12:14:24 66.60 96 Sell* 63.94 A
12:14:24 66.60 2,211 Sell* 1,473 A
12:14:24 66.20 2,571 Sell* 1,702 A
12:14:24 66.20 2,007 Sell* 1,329 A
12:14:24 66.60 2,307 Sell* 1,536 A

12:14:25 66.00 1,677 Sell* 1,107 A
12:14:25 66.00 3,323 Sell* 2,193 A
12:14:25 66.00 2,583 Sell* 1,705 A
12:14:25 66.00 185 Sell* 122.10 A
12:14:25 66.10 1,700 Sell* 1,124 A
12:14:25 66.10 5,000 Sell* 3,305 A
12:14:25 66.00 3,732 Sell* 2,463 A
12:14:25 66.60 1,700 Sell* 1,132 A
12:14:25 66.60 1,453 Sell* 967.70 A

The reason the likes of Woodford and BG invested so heavily here driving the price up to £10 a share was because 4D and other microbiome companies are not just offering a couple of new drugs. They are offering a new branch of medicine.

When the above invested it was on the potential of realising that dream. 4D have gone some way to putting the foundations in place to achieve that with LBPs targeting oncology, auto immune diseases, gastro intestinal and neurological.

We need to think big with this one.

Baillie Gifford were the reason I invested here for the 1st time in 2018. I don't know if they participated in the last placing but they did in the 1 before that.

I heard the manager of the Fidelity Special Situations fund make a positive reference to 4D last year but I wasn't sure if they were invested.

"Reported successes reinforcing market value include the positive Phase III results attained by Seres Therapeutics’ leading candidate SER-109, which significantly reduced recurrence rates of C. difficile infection. Encouraging clinical data have also been reported by the Ferring-owned microbiome firm Rebiotix as well as major player Finch Therapeutics. However, outcomes from the collaboration between Merck and 4D Pharma have garnered attention as a key value-adding event. When combined with Keytruda, 4D’s candidate MRx0518 managed to exceed the predetermined threshold for disease control rate (DCR) of 10% to obtain 42% in patients refractory to prior immune checkpoint inhibitor (ICI) therapy, with monotherapy data demonstrating single-agent immunomodulation.
Aims to further evaluate its lead single-strain live biotherapeutic product in new combinations and in earlier treatment settings are therefore unsurprising, with 4D Pharma reporting a clinical trial collaboration and supply agreement with Merck KGaA and Pfizer for Bavencio.

Evidently, immune checkpoint inhibitors have revolutionized cancer therapeutics; however, most patients fail to respond to these agents. Merck therefore stands to benefit, as 4D Pharma may provide an avenue to overcome resistance to checkpoint inhibitors, thereby increasing the addressable market; advantageously, live biotherapeutics are anticipated to have a favorable safety profile"

https://www.clinicaltrialsarena.com/comment/microbiome-therapeutics-immuno-oncology-agents/

I am referring to the directors in case not clear

Also if they have insight into the readouts from the 0518 ongoing it wouldn't look good if they were buying.

They have only ever bought in placings.

It's difficult for UK IIs to buy Aim stocks as they are seen as too risky for the majority of funds.
I imagine US investors are waiting for more data.

Not about to

I have sold everything except Angle Researcher1

I don't think it's that. I am just working on a 3 year minimum time frame. If there is a short term recovery I will probably reduce exposure. Otherwise happy to hold the bag

No trading mate. Conviction investing I believe they call it.

Just got another 6224 shares

I imagine there has been some. But if he is having to sell because he needs the money today, then there's not much they can say.

It is a case of good riddance. There is not much info available about Steven Michael Oliveira but I did come across some questioning his reputation with regard to some of his past dealings.

He is also banned by Finra from carrying out brokerage activities

He is a US investor who cares little for the notification rules. He has been selling since the 2 September and the only notification he has provided so far was up until the 13th.
He had 14.5m. He has sold at least 500k shares so far today. There can't be that many left to go. He only held 8% of the UK shares and it's down
30% since he started selling